Sodium phenylbutyrate/tauroursodeoxycholic acid - Amylyx Pharmaceuticals

Drug Profile

Sodium phenylbutyrate/tauroursodeoxycholic acid - Amylyx Pharmaceuticals

Alternative Names: AMX 0035; Tauroursodeoxycholic acid/sodium phenylbutyrate

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amylyx Pharmaceuticals
  • Class Antidementias
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis
  • Preclinical Alzheimer's disease; Friedreich's ataxia

Most Recent Events

  • 24 Oct 2017 Amylyx Pharmaceuticals plans a phase II trial for Alzheimer's disease in 1H 2018 (CTP#289683)
  • 19 Sep 2017 Sodium phenylbutyrate/tauroursodeoxycholic acid receives Orphan Drug status for Amyotrophic lateral sclerosis in USA
  • 07 Aug 2017 Preclinical trials in Friedreich's ataxia in USA (PO) before August 2017 (Amylyx Pharmaceuticals pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top